Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes how anifrolumab, used beyond trial-eligible populations, led to significant clinical and serological recovery in a 45-year-old woman with organ-threatening systemic lupus erythematosus complicated by infection and resistant to conventional treatments like cyclophosphamide and rituximab.

Rituximab treatment led to complete hair regrowth and improved skin in a woman with pemphigus foliaceus.

This article discusses arsenic trioxide as a treatment for refractory or relapsed acute promyelocytic leukemia, noting its effectiveness and manageable side effects.

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.

This article reviews new drug combinations and unique agents for rheumatoid arthritis but reports no clinical results; the authors highlight several promising compounds awaiting approval.

This study found that both intralesional pentoxifylline and intralesional corticosteroids improved hair regrowth in patients with localized alopecia areata, but intralesional corticosteroids were more effective, achieving 100% hair regrowth compared to 60% with pentoxifylline.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

This study observed that among children with neurofibromatosis type 1 in Russia, selumetinib treatment led to a partial reduction in plexiform neurofibroma volume in 65% of cases, with 56% showing a long-term response without surgery; common side effects included skin rash and hair issues.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

This clinical study observed that in patients with advanced breast cancer and BRCA1/2 mutations, talazoparib provided significantly better progression-free survival, objective response, clinical benefit, and patient-reported outcomes compared to physician’s choice chemotherapy, despite common side effects like anemia and fatigue.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

JAK inhibitors, like baricitinib and ritlecitinib, show promise in treating alopecia areata effectively and safely.

This study suggests that IV delivery of ExoFlo may be a safe and effective treatment for addressing symptoms in CRPS patients, warranting further investigation.

In this study, researchers report that CDK inhibitors like palbociclib and ribociclib, initially developed for cancer therapy, show potential in treating neutrophilic inflammation-related conditions such as ARDS and psoriasis, although their clinical repurposing requires further research on safety and dose adjustments.

This study reported two cases where infliximab-associated psoriasiform alopecia resolved with significant hair regrowth after stopping infliximab and using potent topical steroid treatment.

This source reports that tofacitinib and ruxolitinib showed potential efficacy and acceptable safety profiles in treating various autoimmune disorders, including alopecia areata and psoriasis, based on a review of clinical studies, while recommending physicians consider the individual risks and benefits.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

In this pilot study, combined platelet-rich plasma therapies showed potential benefits for improving skin elasticity and vascular network density in morphea patients, but the small sample size limits definitive conclusions.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.

In this case report, two patients with polyautoimmunity and difficult-to-treat lupus erythematosus experienced significant symptom improvement after adding anifrolumab to their regimen, suggesting its potential as an effective add-on therapy for refractory cutaneous symptoms in autoimmune conditions characterized by elevated interferon alpha activity.

Certain peptides can prevent hair loss in young rats caused by a cancer drug.

Ixekizumab effectively treats generalized pustular psoriasis.

This study identified mefloquine as a potent inducer of lethal ER stress that effectively eliminated vemurafenib-resistant and sensitive melanoma cells, suggesting its potential for repurposing as a melanoma treatment.

This study reported that the combination of EE-CPA and raloxifene effectively manages PCOS-related infertility, enhancing pregnancy outcomes through improvements in metabolism, sex hormones, ovarian function, and endometrial receptivity, without significantly increasing adverse effects.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.

This study found that in first-line treatment of metastatic breast cancer, pegylated liposomal doxorubicin (PLD) provided similar progression-free survival to doxorubicin with significantly less cardiotoxicity.

This review found that platelet-rich plasma therapy may enhance ovarian repair and fertility outcomes in ovarian insufficiency, but notes that optimal usage and long-term effects require further investigation.

This document provides a legal disclaimer and offers no research findings.

In this study, four children with recurrent atypical teratoid rhabdoid tumors experienced disease stabilization or regression after treatment with alisertib, suggesting its potential role in future trials for this condition.

This review discusses the potential role of JAK inhibitors, like ruxolitinib, as emerging therapeutic agents in dermatology, but reports no new clinical results.